Walmart-Flipkart deal: SoftBank CEO Masayoshi Son confirms Walmart buying Flipkart

Walmart-Flipkart deal: SoftBank CEO Masayoshi Son confirms Walmart buying Flipkart

PTIUpdated: Wednesday, May 29, 2019, 09:30 AM IST
article-image

New Delhi: US retail giant Walmart will buy a majority stake in India’s largest e-commerce company Flipkart, according to the head of SoftBank, a major stakeholder in the Indian firm.

US retail giant Walmart will buy a majority stake in India’s largest e-commerce company Flipkart, according to the head of SoftBank, a major stakeholder in the Indian firm.

“Last night, (they) reached a final agreement and it was decided that Flipkart will be sold to America’s Walmart,” said SoftBank CEO Masayoshi Son, whose firm owns a 20 per cent stake in Flipkart.

Walmart Inc and Flipkart’s mega deal which will see the US-retailer picking up significant majority stake in the Indian e-commerce major for close to USD 15 billion, sources said. The deal will see some of the biggest investors in Flipkart offloading their holding in the country’s largest e-commerce company. Japan’s SoftBank Group Corp and Tiger Global Management are said to be selling almost all of their about 20 per cent stake each in Flipkart.

If all goes well, Walmart will likely end up with 60-80 per cent of Flipkart, valuing the company at upwards of USD 20 billion, the sources said.

(With AFP inputs)

RECENT STORIES

Meta Shares Crash Over 10% As Anxiety Over Success Of AI Surges

Meta Shares Crash Over 10% As Anxiety Over Success Of AI Surges

Land Rover Defender Octa: Most Powerful Version Set to Debut on July 3rd

Land Rover Defender Octa: Most Powerful Version Set to Debut on July 3rd

UK-TIK TOK Ban: How Other Countries are Restricting it

UK-TIK TOK Ban: How Other Countries are Restricting it

Shriram Finance Q4 Results Announces a 150% Dividend, 450% Dividend in a Year

Shriram Finance Q4 Results Announces a 150% Dividend, 450% Dividend in a Year

Opioid Overkill: McKinsey Under Probe For Maximizing Sale Of Drugs

Opioid Overkill: McKinsey Under Probe For Maximizing Sale Of Drugs